ライフサイエンスコーパス: immunosuppressant

1 y, pancreatitis, systemic steroids, or other immunosuppressants).

2 as an increase in the dose of steroid and/or immunosuppressant.

3 in (IL)-2 receptor antibody as a maintenance immunosuppressant.

4 -like antitumor agents; and a rapamycin-like immunosuppressant.

5 in conjunction with a conventional clinical immunosuppressant.

6 wo across a class I MHC disparity without an immunosuppressant.

7 nflammatory bowel disease (IBD) treated with immunosuppressants.

8 or-specific tolerance, minimizing the use of immunosuppressants.

9 of the patients received corticosteroids or immunosuppressants.

10 nse to conventional therapy with steroids or immunosuppressants.

11 plants from 1984 to 2008 treated with modern immunosuppressants.

12 rrent treatment with oral corticosteroids or immunosuppressants.

13 ds the therapeutic utility of these drugs as immunosuppressants.

14 tivation and proliferation and are effective immunosuppressants.

15 e 5-aminosalicylic acid drugs, steroids, and immunosuppressants.

16 recipients due to the use of lower doses of immunosuppressants.

17 y mice (Mus sp.) without the aid of powerful immunosuppressants.

18 t standard of care involves the reduction of immunosuppressants.

19 (88%) involved the concomitant use of other immunosuppressants.

20 oving quality of care for patients receiving immunosuppressants.

21 tation rates in rheumatology patients taking immunosuppressants.

22 e, are widely employed anticancer agents and immunosuppressants.

23 fficacy in controlling uveitis refractory to immunosuppressants.

24 itive patients who have not previously taken immunosuppressants.

25 oids, combined or not with other traditional immunosuppressants.

26 ally leading to resistance to CD28-targeting immunosuppressants.

27 trolling for important confounders including immunosuppressants.

28 izumab treatment, and with prior exposure to immunosuppressants.

29 roids and, for more severe disease, systemic immunosuppressants.

30 13 on hemodynamic and fluid management, 7 on immunosuppressants, 12 on preconditioning, 34 on preserv

31 recipients than heart recipients for taking immunosuppressants (13% nonadherent vs. 21%, respectivel

32 rganizing protein Drebrin as a target of the immunosuppressant 3,5-bistrifluoromethyl pyrazole, which

33 d P2Y12, and at P2X4 and P2X7 receptors), an immunosuppressant (acting at P2Y11), and a growth-promot

34 Streptomyces sp. IUK-102 and exhibits potent immunosuppressant activity (IC(50) = 70 nM).

35 ormones that possesses anti-inflammatory and immunosuppressant activity and is commonly used to treat

36 further demonstrating the specificity of the immunosuppressant activity of CP.

37 rol by means of conventional and/or biologic immunosuppressants after remission-induction with anti-B

38 The immunosuppressant agent mycophenolic acid (MPA) has show

39 No clear association was found with any 1 immunosuppressant agent.

40 etween antiretrovirals (ARVs) and transplant immunosuppressant agents (IS) among HIV-infected transpl

41 h corticosteroids in combination with global immunosuppressant agents and/or immunomodulatory monoclo

42 unosuppression with corticosteroids or other immunosuppressant agents such as infliximab; most irAEs

43 ng-standing kidney disease and/or neurotoxic immunosuppressant agents.

44 ce (KCa3.1) is a target for antisickling and immunosuppressant agents.

45 sible in view of evidence that arsenic is an immunosuppressant and also a cause of chronic lung disea

46 1 inhibitor with clinical applications as an immunosuppressant and anti-cancer agent.

47 anti-proliferative properties, which give it immunosuppressant and anti-tumor activity.

48 topurine have been extensively prescribed as immunosuppressant and anticancer agents for several deca

49 The DNA of patients taking the immunosuppressant and anticancer drugs azathioprine or 6

50 diolipins and show that prior binding of the immunosuppressant and antifungal antibiotic cyclosporin

51 (also called fingolimod) is recognized as an immunosuppressant and has been approved by the Food and

52 FTY720-P, a phosphorylated derivative of the immunosuppressant and vasoactive compound FTY720.

53 Thiopurines are effective immunosuppressants and anticancer agents, but intracellu

54 ety of other drugs such as antitumor agents, immunosuppressants and antifungals.

55 rotocols should allow for improved dosing of immunosuppressants and better management of posttranspla

56 BS sampling for the simultaneous analysis of immunosuppressants and creatinine can replace convention

57 hildren in Group A were treated earlier with immunosuppressants and had more frequent endoscopic asse

58 sing encapsulation may circumvent the use of immunosuppressants and prolong the longevity of transpla

59 ) between the groups; neither were secondary immunosuppressants and use of steroids.

60 avenous immunoglobulin, plasma exchange, and immunosuppressants) and ambulatory outcomes were compare

61 es several validated targets for anticancer, immunosuppressant, and anti-inflammatory chemotherapeuti

62 success was achieved in 74% of patients on 1 immunosuppressant, and in an additional 21% of patients

63 drug intolerance compared with other primary immunosuppressants, and discontinuation rates are partic

64 C virus antibodies, prior or no prior use of immunosuppressants, and duration of treatment (1 to 24 m

65 cancer treatment, as antiviral drugs and as immunosuppressants, and have also displayed antibiotic a

66 ct to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizuma

67 ct to anti-JC virus antibodies, prior use of immunosuppressants, and increasing duration of natalizum

68 r more therapy lines, including splenectomy, immunosuppressants, and rituximab.

69 uenced positively or negatively by different immunosuppressants, and the impact of exhaustion on graf

70 5-aminosalicylate (5-ASA), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF) the

71 Patients treated with immunosuppressant/anti-inflammatory thiopurines are also

72 class of red-pigmented natural products with immunosuppressant, anticancer, and antimalarial activiti

73 Topical as well as systemic immunosuppressants are administered for prophylaxis.

74 Immunosuppressants are an important cause of posttranspl

75 Tacrolimus is a new-generation immunosuppressant as successful as cyclosporin in suppre

76 mmune system, whereas clobetasol is a potent immunosuppressant as well as a remyelinating agent.

77 r the first time the potential usefulness of immunosuppressants as tolerogenic adjuvants.

78 mus and 26.2% were also receiving adjunctive immunosuppressants at the last follow-up.

79 cineurin inhibitor with sirolimus as primary immunosuppressant attenuates long-term cardiac allograft

80 Among these, the immunosuppressant azathioprine and the fluoroquinolone a

81 The immunosuppressant azathioprine, the fluoroquinolone anti

82 ls inaugurates the arrival of a new class of immunosuppressants based on costimulatory blockade, an i

83 tors have received considerable attention as immunosuppressants because they are associated with a mo

84 tive for anti-JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab

85 Patients who received steroids or other immunosuppressants before transplantation had lower resp

86 study establishes that "LxVP" sequences and immunosuppressants bind to the identical site on CN.

87 ch as cyclosporine A and FK506 are effective immunosuppressants but produce severe side effects.

88 sors not only resisted many tumor-associated immunosuppressants, but also responded to tumor contact

89 by S. aureus and moonlights as a macrophage immunosuppressant by reducing Toll-like receptor 1/2 (TL

90 Immunosuppressants can induce hepatitis B virus (HBV) re

91 that dexamethasone, a potent glucocorticoid immunosuppressant, can function as a tolerogenic adjuvan

92 himaera were more likely to be prescribed an immunosuppressant compared with all other patients (AOR,

93 duscin's aglycone, and bacterial cell-coated immunosuppressants could be a general strategy to combat

94 l of whom were affected by BIPA by extending immunosuppressant coverage under BIPA.

95 Thalassospiramides A and B are immunosuppressant cyclic lipopeptides first reported fro

96 Moreover, effects of the prototypic immunosuppressant cyclosporin A (CsA) were investigated.

97 ta for the complex of cyclophilin A with the immunosuppressant cyclosporin A.

98 contrast, treating activated rCD4s with the immunosuppressant cyclosporin, a calcineurin inhibitor,

99 , and these dynamic changes are inhibited by immunosuppressants cyclosporin A and triptolide.

100 either a proteasome inhibitor Velcade or an immunosuppressant cyclosporine A.

101 ) best known as the cellular receptor of the immunosuppressant cyclosporine A.

102 Organ transplant recipients using the immunosuppressant cyclosporine have an increased risk fo

103 imals receiving intestinal grafts without an immunosuppressant developed antidonor IgG in 14 days and

104 to 25 cases per 100 PPY for nonadherence to immunosuppressants, diet, exercise, and other healthcare

105 cate that the interaction between UVA and an immunosuppressant drug causes photochemical DNA lesions,

106 Calcineurin is inhibited by the immunosuppressant drug cyclosporine A (CsA) or tacrolimu

107 ze associations between NR1I2 polymorphisms, immunosuppressant drug exposure, and clinical outcomes i

108 Moreover, nasal administration of the immunosuppressant drug FTY720/fingolimod reduced ORMDL3

109 ur in transplant recipients treated with the immunosuppressant drug rapamycin (sirolimus).

110 The immunosuppressant drug rapamycin exerts its therapeutic

111 The immunosuppressant drug tacrolimus (FK506) reduces dopami

112 Compliance with complex immunosuppressant drug therapies in transplant recipient

113 There were differences in the immunosuppressant drug therapy in monotherapy as well as

114 g site of the 12-kDa binding protein for the immunosuppressant drug, FK506.

115 tential to be developed as a new category of immunosuppressant drugs acting via autophagy induction o

116 This Review describes the use of intense immunosuppressant drugs and natalizumab in patients with

117 agues show in this issue of the JCI that the immunosuppressant drugs clinically inhibit beta cell pro

118 pendent phosphatase that is inhibited by the immunosuppressant drugs cyclosporine and tacrolimus.

119 FK506-binding protein 12 (FKBP12) binds the immunosuppressant drugs FK506 and rapamycin and regulate

120 Transplant patients treated with immunosuppressant drugs such as cyclosporine A (CsA), an

121 Immunosuppressant drugs such as cyclosporine and tacroli

122 can be rapidly adopted for the detection of immunosuppressant drugs, alpha-amylase protein, or prote

123 transducing functions and susceptibility to immunosuppressant drugs.

124 d risk of side effects with prolonged use of immunosuppressant drugs.

125 -76 mg/L]; P=0.006) and a trend toward fewer immunosuppressants drugs used before biologics (P=0.054)

126 although combinations of glucocorticoids and immunosuppressants (e.g., cyclophosphamide, azathioprine

127 Several studies on other immunosuppressants, either as a steroid-sparer, steroid

128 Immunosuppressants, erythropoiesis-stimulating agents in

129 n and often requires treatment with systemic immunosuppressants, extracorporeal photopheresis, or pho

130 to the tumor antigen, and treatment with the immunosuppressant FK506 (tacrolimus) decreases CSF white

131 sruption of the Hom3:Fpr1 interaction by the immunosuppressant FK506, illustrating the assay's capaci

132 PPIase) activity which is inhibitable by the immunosuppressants FK506 and rapamycin.

133 endent ser/thr phosphatase and the target of immunosuppressants, FK506 and cyclosporin A (CSA).

134 d at investigating the efficacy of the novel immunosuppressant FK778 to prevent the development and p

135 The critical role of CsA/FK506 as an immunosuppressant following transplantation surgery prov

136 hloroquine is the most frequently prescribed immunosuppressant for the syndrome.

137 ansplant patients, FK778 (an investigational immunosuppressant from the malononitrilamides class) was

138 e of drugs, including chemotherapy drugs and immunosuppressants, from cells.

139 The clinical immunosuppressant FTY720 is a sphingosine analogue that,

140 Notably, two seemingly unrelated immunosuppressants, FTY720 and rapamycin, targeted the s

141 immunosuppressant group and 24 months in the immunosuppressant group.

142 The use of topical immunosuppressants has been anecdotally reported for the

143 ith aquaporin-4 antibodies who are receiving immunosuppressants has not been reported to date.

144 Transplant immunosuppressants have been implicated in the increased

145 ustment for confounders including the use of immunosuppressants, having NASH was independently associ

146 lmonary fibrosis by increasing levels of the immunosuppressant IL-10.

147 potentially linked to side effects of their immunosuppressants.Immunosenescence is a physiological p

148 chanism through which a clinically important immunosuppressant impedes the capacity of DC to mature a

149 Sirolimus is being used increasingly as an immunosuppressant in allogeneic hematopoietic stem cell

150 f conversion to sirolimus (SRL) as a primary immunosuppressant in attenuating cardiac allograft vascu

151 ing into question the use of rapamycin as an immunosuppressant in islet transplantation and as a seco

152 Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients.

153 yzed the potential of sirolimus as a primary immunosuppressant in the long-term attenuation of cardia

154 S1P analogue FTY720 has been developed as an immunosuppressant in transplantation and tested as a tre

155 with systemic steroids in 28 cases (61%) and immunosuppressants in 32 cases (69.5%).

156 antigen (HLA) antibodies after withdrawal of immunosuppressants in 35 type 1 diabetic recipients of i

157 m for the off-label prescription of systemic immunosuppressants in AD, discusses the apparent dilemma

158 Combination of two immunosuppressants in addition to steroids may be indica

159 ndations on endpoints for clinical trials on immunosuppressants in lung transplantation.

160 the way to study the differential effects of immunosuppressants in posttransplantation malignancy.

161 eparations are one of the most commonly used immunosuppressants in the United States.

162 esting approach for narrow therapeutic index immunosuppressants in transplant recipients have been la

163 sphatase calcineurin, an important target of immunosuppressants in transplantation biology.

164 In a model of immunosuppressant-induced hyperglycemia, both TAC and SI

165 rst study to show that metformin can improve immunosuppressant-induced hyperglycemia, when administer

166 to selectively inactivate immune cells with immunosuppressants is a much sought-after modality for t

167 n multivariate analysis, treatment with both immunosuppressant (IS) and anti-TNF before colectomy was

168 addition, rapamycin, a clinically important immunosuppressant, is a specific and potent inhibitor of

169 Azathioprine, a widely used immunosuppressant, is also used in the control of inflam

170 uppressants out of leukocytes, with depleted immunosuppressant levels in leukocytes manifesting as in

171 Adherence was evaluated via self-report and immunosuppressant levels.

172 sure to determine the best method to monitor immunosuppressant levels.

173 Adenosine is a powerful immunosuppressant (mainly acting at A2A receptors) and a

174 RQoL, suggesting that use of non-nephrotoxic immunosuppressants may affect the patient's side effect

175 ism by which FTY720, a synthetic sphingosine immunosuppressant, mediated antitumor effects in hepatoc

176 Mycophenolate mofetil is a potent immunosuppressant medication approved by the Food and Dr

177 adherers perceived that their transplant and immunosuppressant medication caused more symptoms and we

178 Nonadherence to immunosuppressant medication is a significant problem am

179 oimmune recurrence, alloimmune rejection, or immunosuppressant medication toxicity.

180 ey transplantation including nonadherence to immunosuppressant medication, graft failure, and all-cau

181 topenias, possibly in combination with other immunosuppressant medication.

182 The introduction of generic immunosuppressant medications may present an opportunity

183 rimary insurance, time since transplant, and immunosuppressant medications using the STATA software (

184 e most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide.

185 medications are associated with adherence to immunosuppressant medications.

186 kedly between centers (range, 0%-58%) and by immunosuppressant medications.

187 ous and aggressive in patients taking T-cell immunosuppressant medications.

188 days in the absence of any corticosteroid or immunosuppressant medications.

189 food allergen avoidance, and use of systemic immunosuppressant medications.

190 or multiple sclerosis, previous therapy with immunosuppressants might increase risk.

191 Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1bet

192 ry, rats of both lines were treated with the immunosuppressant mycophenolate mofetil (MMF).

193 Clinical studies suggest that the immunosuppressant mycophenolate mofetil is associated wi

194 Immunosuppressant mycophenolate mofetil treatment of enr

195 novel nanogel drug delivery vehicle for the immunosuppressant mycophenolic acid (MPA).

196 ntation (n=4) or were treated with long-term immunosuppressants (n=3).

197 actice of anti-JCV antibody index testing of immunosuppressant-naive patients with MS, either current

198 gnificantly by transplant type in two areas: immunosuppressant nonadherence was highest in kidney rec

199 investigated the effect of morphine, a known immunosuppressant, on leukocyte migration and recruitmen

200 tion of penicillins (OR, 6.12; P = .03), and immunosuppressants (OR, 7.00; P = .002); (2) day 7, base

201 olved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxi

202 1/ABCB1 encoded P-gp mediating the efflux of immunosuppressants out of leukocytes, with depleted immu

203 l approaches, we mapped the receptor for the immunosuppressant PAP-1 (5-(4-phenoxybutoxy)psoralen), a

204 agectomy with neoadjuvant therapy is also in immunosuppressant patients feasible without increased ri

205 Azathioprine, a purine antimetabolite immunosuppressant, photosensitizes the skin and causes t

206 lmodulin-regulated phosphatase and target of immunosuppressants, plays important roles in the circula

207 The immunosuppressant rapamycin (RAPA) inhibits mTORC1 but n

208 rated via FNP that were dual loaded with the immunosuppressant rapamycin and a fluorescent dye to lin

209 The immunosuppressant rapamycin frequently causes noninfecti

210 s increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older patients.

211 meters were gender, age, transplanted organ, immunosuppressant regimen, time between transplantation

212 replication under therapy and the impact of immunosuppressant regimens on viral replication are unkn

213 y was to determine clinical, laboratory, and immunosuppressant-related factors associated with kidney

214 is lost through multiple factors, including immunosuppressant-related toxicity, often requiring more

215 ween myositis (and other immune-mediated and immunosuppressant-responsive disorders) and its many cli

216 ydroxyphenylalanyl-(3S)-piperazate common to immunosuppressant sanglifehrins was synthesized from the

217 t factors with which to guide individualized immunosuppressant selections over time.

218 also loaded with cyclophosphamide (CYC), an immunosuppressant shown to reduce the cerebrovascular in

219 Although regarded primarily as an immunosuppressant signal, cAMP has been found to mediate

220 o improve outcome, innovative management and immunosuppressant strategies were sequentially evolved.

221 s, 96 patients) and find that antivirals and immunosuppressants strongly affect the structure of the

222 There was no correlation between immunosuppressant studied drugs and any of the studied v

223 amethasone is a potent anti-inflammatory and immunosuppressant substance.

224 e, including antibiotics such as penicillin, immunosuppressants such as cyclosporine, and cytostatics

225 Treatment with immunosuppressants such as rituximab, azathioprine and c

226 suppress in allograft recipients exposed to immunosuppressants, such as tacrolimus (TAC).

227 approval of narrow therapeutic index generic immunosuppressants, such as tacrolimus, in transplant re

228 ytotoxicity of the calcineurin inhibitor and immunosuppressant tacrolimus (FK-506) was prevented by N

229 The effect of an immunosuppressant, Tacrolimus, is also confirmed in the

230 e occurred in 16 (55%) of 29 patients during immunosuppressant taper or discontinuation.

231 ycophenolic acid (MPA) is a highly effective immunosuppressant that has broad antiviral activity agai

232 Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe di

233 , Fingolimod) represents a new generation of immunosuppressant that modulates lymphocyte trafficking

234 FTY720 is an immunosuppressant that promotes lymphocyte sequestration

235 2CA acts as narrow-spectrum immunosuppressant that selectively targets lymphocyte po

236 1/3 inhibitor R507 is a very well-tolerated immunosuppressant that similarly diminished obliterative

237 urrently treated using mainly broad-spectrum immunosuppressants that can lead to adverse side effects

238 res treatment with nonspecific pharmacologic immunosuppressants that carry both systemic and nephrolo

239 nses can be limited with the use of systemic immunosuppressants, the induction of regulatory cell pop

240 6 may represent an optimal target for future immunosuppressant therapeutics with a particular role in

241 n the conventional management group required immunosuppressant therapy (61%; median time to first pre

242 ), only 1/14 patients achieved response with immunosuppressant therapy alone.

243 ents achieved response with a combination of immunosuppressant therapy and thrombopoietin-receptor ag

244 Early aggressive immunosuppressant therapy improved outcomes, and risk of

245 splant recipients (RTRs) at highest risk for immunosuppressant therapy nonadherence.

246 Patients often must choose between long-term immunosuppressant therapy or total colectomy.

247 Immunosuppressant therapy reduced the relapse rate in bo

248 Combining an immunosuppressant therapy with thrombopoietin-receptor a

249 traocular tissue transplantation, multiagent immunosuppressant therapy, and bioartificial devices suc

250 e or >or=2 BILAG B scores despite background immunosuppressant therapy, which was continued during th

251 d infectious contexts, and/or anti-rejection immunosuppressant therapy.

252 ent cohort included 76 patients who received immunosuppressant therapy; the remaining 82 patients did

253 erlying illnesses and the use of concomitant immunosuppressants; therefore, a clear causal relationsh

254 Long-term treatment with the anticancer and immunosuppressant thiopurines, azathioprine or 6-mercapt

255 modulin to stimulate binding of immunophilin/immunosuppressant to calcineurin.

256 ought to establish the ability of a systemic immunosuppressant to modulate immune and epidermal alter

257 ence supports therapeutic monitoring of this immunosuppressant to optimize its efficacy and reduce to

258 steroid-resistant disease is to add a single immunosuppressant to the regime, with additional agents

259 The addition of transplant immunosuppressants to an already immunocompromised state

260 oactive compounds, ranging from statins over immunosuppressants to antibiotics.

261 identified as pharmacological receptors for immunosuppressants to regulate immune responses via isom

262 When combined with immunosuppressant toxicity, post-transplant diabetes and

263 ntibodies are being identified and receiving immunosuppressant treatment earlier and more aggressivel

264 Patients were divided into 2 subgroups: an immunosuppressant treatment group and a nonimmunosuppres

265 nd understand the putative new bile acid and immunosuppressant treatment strategies under development

266 A vaccination BPA was developed based on immunosuppressant treatment, age, and prior vaccinations

267 Randomisation was stratified by baseline immunosuppressant treatment.

268 In patients without previous immunosuppressant use (n=18 616), estimated annual PML r

269 % (95% CI 1.8-4.0) in patients with previous immunosuppressant use and 1.7% (1.4-2.1) in those withou

270 Neither natalizumab exposure nor prior immunosuppressant use appear to affect prevalence.

271 Higher serum C3 levels and immunosuppressant use at baseline were related to plaque

272 cumulative PML risk with or without previous immunosuppressant use was estimated using Kaplan-Meier a

273 am virus (JCV) antibodies in serum, previous immunosuppressant use, and treatment duration, which wer

274 In patients with no prior immunosuppressant use, anti-JCV antibody index distribut

275 gy for cephalosporins, known kidney disease, immunosuppressant use, or pregnancy.

276 regardless of natalizumab exposure or prior immunosuppressant use, p = 0.9709 and p = 0.6632, respec

277 antibody-positive patients without previous immunosuppressant use, risk estimates were further strat

278 Nonadherence rates in some areas--including immunosuppressant use--appear unacceptably high.

279 ues of anti-JCV antibody status and previous immunosuppressant use.

280 antibody-positive MS patients with no prior immunosuppressant use.

281 mammalian target of rapamycin (mTOR) and an immunosuppressant used for the prevention of renal trans

282 rin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to prevent allograft rejection, c

283 ine and tacrolimus are calcineurin inhibitor immunosuppressants used to prevent organ rejection after

284 n equation approach revealed that the use of immunosuppressants was an independent predictor for slow

285 ystemic corticosteroids, antihistamines, and immunosuppressants was unsuccessful.

286 In an effort to discover novel immunosuppressants we used cytokine ELISPOT and ELISAs t

287 Calcineurin inhibitor-based immunosuppressants were given.

288 filtration rates, and concentrations of the immunosuppressants were measured along with (1)H-magneti

289 The associated immunosuppressants were tapered after administering 3 ad

290 Secondary immunosuppressants were unchanged.

291 er drugs (eg, penicillins, fluoroquinolones, immunosuppressants) were the strongest predictors of ren

292 Although morphine is a known immunosuppressant, whether it directly induces virulence

293 alcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allogr

294 ELPs) fused with FKBP12, to deliver a potent immunosuppressant with dose-limiting toxicity, rapamycin

295 thermore, immunosuppression therapy based on immunosuppressants with antitumoral effects should be pr

296 iscovery effort to identify HO-1/CO-targeted immunosuppressants with dual target specificity.

297 Both R507 and R545 are potent novel immunosuppressants with favorable pharmacokinetics and h

298 Allograft survival despite complete immunosuppressant withdrawal has been demonstrated in se

299 erogenic therapies, and to allow intelligent immunosuppressant withdrawal in patients whose autoimmun

300 Immunosuppressant withdrawal resulted in CDC positivity